Mein Warenkorb

GITR

GITR Molekülinformation

Englischer NameGlucocorticoid-induced tumor necrosis factor receptor-related proteinAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4Target-AliasTNFRSF18,TNF Receptor Superfamily Activation-Inducible Protein,ENERGEN,GITR-D,Tumor Necrosis Factor Receptor Superfamily Member 18,CD357 Antigen,Activation-Inducible TNFR Family Receptor,AITR,CD357,GITR,Glucocorticoid-Induced TNFR-Related Protein,Tumor Necrosis Factor Receptor Superfamily, Member 18,TNF Receptor Superfamily Member 18
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameGlucocorticoid-induced tumor necrosis factor receptor-related protein
Target-AliasTNFRSF18,TNF Receptor Superfamily Activation-Inducible Protein,ENERGEN,GITR-D,Tumor Necrosis Factor Receptor Superfamily Member 18,CD357 Antigen,Activation-Inducible TNFR Family Receptor,AITR,CD357,GITR,Glucocorticoid-Induced TNFR-Related Protein,Tumor Necrosis Factor Receptor Superfamily, Member 18,TNF Receptor Superfamily Member 18
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

GITR Molekülhintergrund

Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway.

GITR Molekülalias

AITR,GITR,TNFRSF18,CD357

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
BMS-986156BMS-986156Phase 2 ClinicalBristol-Myers Squibb CompanyLiver Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Thoracic Neoplasms
Details
RagifilimabINCAGN-1876; INCAGN-01876; AGEN-1876; CM-701Phase 2 ClinicalAgenus Inc, Ludwig Institute For Cancer ResearchNeoplasm Metastasis; Neoplasms
Details
Anti-GITR antibody (BMS)Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms
Details
IBI-102IBI102; IBI-102Phase 1 ClinicalNeoplasms
Details

Produktrezensionen

  • 1***32019-09-27
    1Menschen mögen
    I have been using Acro's products for a long time. Whenever there is some concerns on product or technical support is needed, it always gets solved in time. I used the GITR protein for SPR experiments. I have done 6 concentration gradients, and the fitted curve was still very good. The data also met my expectations. I hope we will continue having a good cooperation with ACRO moving forward.
  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns